Veterinary research and development centre
Germany-based pharmaceutical company Boehringer Ingelheim’s veterinary research and development (R&D) centre is located within its research and development (R&D) site in Shanghai, China.
Officially inaugurated in May 2018, the new facility was developed to strengthen the collaboration between Boehringer Ingelheim and animal health company Merial. The two companies officially merged in January 2017 and teams from both the firms now work together at the centre.
Boehringer invested more than €19m ($22.7m) in the R&D centre, which is the company’s third research facility. The other two are located in Europe and North America.
The R&D facility aims to develop solutions for the prevention and control of animal diseases in China and South East Asia.
The integrated R&D Centre is located in Shanghai’s Zhangjiang Hi-tech Park and covers an area of 3,300m². The facility is currently involved in the discovery and development of 30 ongoing pipeline projects, which include some that have already reached a late phase of development.
Boehringer initially opened a veterinary research centre in March 2012, which was focused on the development of solutions for livestock diseases. The centre formed the base for the development of the new integrated R&D centre.
The centre is expected to launch five novel vaccines targeting the Chinese market by 2020. The veterinary R&D facility has recently launched innovative vaccines NNA and LDT3-A, which are indicated for the treatment of infectious bronchitis.
More than 110 researchers are currently working at the centre.
The animal health business of the company develops vaccines, parasiticides and pharmaceuticals aiming to ensure that no animal suffers from a preventable disease. The unit is also engaged in the development of novel therapies for chronic diseases to manage and reduce disease progression in animals.
The biological R&D team of the unit is engaged in the production of vaccines for pigs, cattle, poultry, horses and companion animals.
China is considered the second biggest market for Boehringer’s animal health business unit. The region contributes to 6.4% of Boehringer’s global sales.
The new R&D facility was set up to further expand the presence of Boehringer’s animal health business in China. The company intends to collaborate with local academic institutions and universities to jointly contribute to the enhancement of its animal health industry in China.
Founded in 1885, Boehringer Ingelheim is one of the biggest pharmaceutical companies in the world. The company is headquartered in Ingelheim, Germany, and has 181 subsidiaries worldwide. It employs more than 50,000 people across all its facilities.
Boehringer operates a biologics manufacturing facility in Zhangjiang Hi-tech Park, which was opened in May 2017 with an investment of €70m ($76m). The company also opened an 8,000m² veterinary trial centre in Taizhou in 2018.
Boehringer recorded revenue of approximately €18.1bn ($21.6bn) in 2017. The company invested approximately €3bn ($3.59bn) in R&D, which accounted for 17% of its total sales.
Boehringer’s animal health business unit has a sales turnover of more than €3.9bn ($4.6bn) and employs more than 10,000 team members worldwide.
Lonza announced the expansion of its bioconjugation facility at its Visp site in Switzerland in December 2020. The expansion will…
Vibalogics announced the development of a late-phase clinical and commercial virotherapy manufacturing facility in Boston, Massachusetts, US, in November 2020.…
Seqirus, an influenza vaccine maker, is building a new cell-based influenza vaccine manufacturing facility in Melbourne, Australia. The facility will…
Thermo Fisher Scientific (Thermo Fisher) will establish a new pharmaceutical services facility for integrated biologics and sterile drug development and…